Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2003

View Archived Issues

Novel adenosine deaminase inhibitors identified at Fujisawa

5-HT1A agonists with utility in the treatment of opioid dependence

New antitumor agents in Pharma Mar development pipeline

Novel X-ray contrast mediums patented by Fuji Photo Film

Pfizer designs new NPY antagonists

Pfizer researchers identify novel opioid ligands for drug abuse, pain, etc.

New CCR5 antagonists in Merck development pipeline

Roche researchers prepare and test novel adenosine A2A ligands

New enediyne-based metal ligands with utility in cancer and viral infections

Direct checkpoint activation: a novel anticancer strategy

Abbott expands Humira development into psoriasis and psoriatic arthritis

Aldara shows benefit in pivotal studies in actinic keratosis and basal cell carcinoma

Approvable letter for Fosrenol

FDA accepts Xoma's BLA for Raptiva

Decitabine declared orphan drug for myelodysplastic syndrome in E.U.

Positive opinion in E.U. for long-term use of Zometa

Large Scale Biology and U. of Arkansas enter agreement for drug intervention therapy

Roche selects MEM-1414 for development for Alzheimer's disease

Phenoxodiol advances through clinical evaluation

FDA advisory committee discusses safety in suspended gene therapy trials

ANA-245 completes phase IA clinical testing

Astex and AstraZeneca enter Alzheimer's drug discovery collaboration

Inhibition of DPP-IV as a potential approach to rheumatoid arthritis

Strong hypoglycemic and antiketotic activity reported following administration of CPT I inhibitor

Potential use of CVT-3146 for myocardial perfusion imaging evaluated in dogs

AstraZeneca begins European roll-out for Crestor

First demonstration that bone marrow can enter the brain and produce neurons in humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...